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ABSTRACT 
SERUM FERRITIN LEVELS IN GESTATIONAL DIABETES MELLITUS 
BACKGROUND: 
The precise mechanisms involved in etio-pathogenesis of gestational diabetes mellitus 
(GDM) are not well understood. Epidemiological data suggest that GDM is associated 
with increased iron stores in the body. Serum ferritin, often used as an indicator of 
body iron stores, has been shown to be increased in those with diabetes mellitus. The 
aim of this study was to determine whether this is so in women with GDM. 
 
MATERIAL AND METHODS: 
A case control study was carried out between January 2017 and July 2018 to recruit 
primigravidae, with and without GDM. Anthropometric data and a fasting blood 
sample were collected from each subject. The blood sample was used to estimate 
serum levels of ferritin, hepcidin, iron, total iron binding capacity (TIBC), percentage 
of transferrin saturation and C–reactive protein (CRP). Clinical data was collected 
from hospital records. 
 
RESULTS: 
Eighty two subjects, 23 women with and 59 women without GDM, were recruited. 
Primigravidae with GDM and those without GDM did not differ with regard to their 
haematocrit values, serum levels of iron, ferritin, transferrin saturation, TIBC, 
hepcidin and CRP values. Serum ferritin bore a significant positive correlation with 
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serum transferrin saturation, and a significant negative correlation with TIBC values. 
Serum hepcidin level bore significant positive correlation with serum iron, ferritin and 
transferrin saturation and a significant negative correlation with TIBC values. The 
gestational ages at delivery, birth weight of the baby, the APGAR score, and length of 
the babies were similar in both groups.  
 
CONCLUSION: 
There were no significant differences in levels of serum ferritin and other iron-related 
parameters in women with and without GDM. Hence, based on the data in this study, 
it does not appear that increased serum ferritin levels may be useful as a marker for 
development of GDM. 
 
Key words:Gestational diabetes mellitus, iron, ferritin, hepcidin 
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REVIEW OF LITERATURE 
INTRODUCTION 
Iron is essential for basic metabolic processes in organisms. It plays a vital role in 
oxygen transport, mitochondrial respiration, nucleotide synthesis and host 
defence(Gulec et al., 2014). Iron exists either in ferrous or ferric form. This feature 
enables it to take part in electron transfer reactions. Hemoglobin, a heme protein 
which helps in oxygen transport, has iron as its prosthetic group. Heme is found in 
other proteins as well, which are collectively referred to as heme proteins. However, 
despite it being essential for life, excessive iron can be harmful. Free iron leads to 
oxidative damage, via the Haber-Weiss and Fenton reactions that generate free 
radicals. Hence, levels of iron must be maintained within physiological limits (Gulec 
et al., 2014). 
Iron in the body is obtained either from absorption from the gut or from recycling of 
iron (from senescent red blood cells) in the reticuloendothelial system. The recycled 
iron contributes the major proportion of iron for the body’s requirements. Dietary iron, 
which is absorbed through the small intestine, contributes much less. However, this 
process is highly regulated and is essential for maintaining iron homeostasis. Unlike 
other nutrients, there is no regulatory mechanism for the excretion of iron from the 
body. Thus, regulation of iron absorption is crucial (Hentze et al., 2010). 
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IRON METABOLISM 
Absorption of iron from the diet 
Iron absorption occurs in the proximal small intestine, mostly in the duodenum 
(Hentze et al., 2010). The amount absorbed is in the range of 1-2 mg/day, and 
contributes less than 10% of the body’s requirement for iron. Dietary iron is found in 
the form of either heme or non-heme iron. The major proportion of dietary iron is non-
heme iron.  
A. Absorption of non-heme iron (Figure 1) 
Non-heme iron in the diet is usually present in its ferric form. In the alkaline 
environment of the duodenum, ferric iron forms insoluble complexes (Przybyszewska 
and Żekanowska, 2014). Duodenal enterocytes cannot take up the ferric form of iron 
(Wollenberg and Rummel, 1987). In order to facilitate iron absorption, the ferric form 
must be converted to its ferrous form. This is accomplished by a brush border ferri-
reductase, duodenal cytochrome b (McKie et al., 2000). This is a transmembrane 
protein that is located on the apical surface of duodenal enterocytes (McKie et al., 
2001). It is a member of the cytochrome b561 family of proteins, the expression of 
which is regulated by iron. Its mRNA and protein levels have been shown to increase 
in iron-deficiency states and in presence of hypoxia (McKie et al., 2001).  
The apical membrane of enterocytes has a protein called divalent metal ion transporter 
1 (DMT1) that takes up the ferrous iron, which is then transported into the cytosol 
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(Gunshin et al., 1997). DMT1 belongs to a family of proteins known as natural 
resistance-associated macrophage proteins (NRAMP). DMT1 is also known as 
NRAMP2 or DCT1 (divalent cation transporter 1). It is a non-specific transporter that 
transports other divalent cations such as Zn
2+
, Cu
2+
, Mn
2+
, Co
2+
, Cd
2+
 and Ni
2+
, 
besides iron (Gunshin et al., 1997).  DMT1 is also present in erythrocytes, where it 
plays a role in pumping iron out of the endosome during the transferrin cycle, 
explained below (Andrews et al., 1999). 
Iron that enters the enterocyte undergoes one of two fates, depending on the body’s 
requirements for iron. It is either stored in the cell (as ferritin, which is a storage 
protein for iron)(Arosio and Levi, 2010)or released into the circulation. Iron inside 
enterocytes is exported into the circulation, by ferroportin, which is present on the 
basolateral surface of enterocytes (McKie et al., 2000). It is encoded by the SLC40A1 
gene and belongs to the family of metal transport 1 proteins (Abboud and Haile, 2000; 
McKie et al., 2001). It is also referred to as IREG1 (iron-regulated transporter 1) or 
MTP1 (metal transport protein 1)(Abboud and Haile, 2000).It is the only known iron 
exporter identified in mammals (Abboud and Haile, 2000). It is highly expressed in 
macrophages, duodenal mucosal cells, hepatocytes, Kupffer cells and placental 
syncytiotrophoblast cells (Abboud and Haile, 2000). Ferroportin knockout mice have 
been shown to have iron-deficiency anemia, highlighting the importance of ferroportin 
in iron absorption (Donovan et al., 2005).  
The duodenal enterocyte also has an enzyme on its basolateral surface, hephaestin, 
which is a ferroxidase that converts the iron into its ferric form (De Domenico et al., 
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2007; Vulpe et al., 1999).It is this form that can bind transferrin, which is the protein 
that transports iron in blood (Schade and Caroline, 1946). 
B. Absorption of heme iron 
Digestive enzymes secreted in the intestine cause proteolytic degradation of heme 
proteins. This results in separation of heme from the protein. The heme is taken up 
into enterocytes by a heme transporter, present on the apical surface of the membrane 
of these cells (Shayeghi et al., 2005). Inside the enterocytes, hemeoxygenase (HO-1) 
releases ferrous iron from heme(Raffin et al., 1974). The released iron follows the 
same fate as that of non-heme iron.  
Figure 1: Absorption of iron in the intestine 
 
 
  
7 
 
Source: Rodwell, V., Bender, D., Botham, K.M., Kennelly, P.J., and Weil, P.A. (2015). Harpers Illustrated 
Biochemistry 30
th
Edition (McGraw Hill Professional). 
 
Recycling of iron by macrophages 
A major part of iron in the body is present in the form of hemoglobin in red blood 
cells (RBCs). Senescent RBCs are phagocytosed by macrophages of the 
reticuloendothelial system, leading to the formation of phagolysosomes. Cytosolic 
heme oxygenase-1 (HO-1) in the macrophages degrades the heme, releasing ferrous 
iron in the phagolysosome(Poss and Tonegawa, 1997). This is transported out of the 
endosome into the cytoplasm by DMT1 (Tabuchi et al., 2000). The ferrous iron then 
either enters the labile iron pool, from where it is transported out of macrophage by 
ferroportin(Donovan et al., 2005),or it is stored in the cell as ferritin. Ceruloplasmin, a 
copper-containing plasma protein in circulation, converts the released ferrous iron to 
its ferric form, which then binds to transferrin in circulation (Harris et al., 1999).Iron 
released by macrophages is the major source of iron for the requirements of the body 
(Zhang and Enns, 2009). 
 
Iron in circulation 
Ferric iron is insoluble; hence, it is transported in blood bound to apo-transferrin ( 
Baker et al., 1994).Transferrin is a bi-lobed glycoprotein synthesized by the liver. 
Apo-transferrin has 2 iron-binding sites, which reversibly bind ferric iron (Luck and 
Mason, 2012). Under physiological conditions, about 30-40% of the binding sites on 
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transferrin are occupied by iron. This represents transferrin saturation, which is a 
reflection of the iron status of the body, and hence a clinically useful marker(Luck and 
Mason, 2012). Under physiological conditions, all the iron in circulation is transferrin-
bound. When there is an iron overload, the excess amount of circulating iron exceeds 
the binding capacity of transferrin (Barisani et al., 1995).  This results in iron in 
circulation that is not bound to transferrin. This unbound iron complexes with citrate 
and albumin in circulation, and is referred to as non-transferrin bound iron (NTBI) 
(Arezes et al., 2013). 
 
Uptake of iron by tissue 
Transferrin, with its bound iron (holo-transferrin), in circulation is taken up into cells 
by receptor-mediated endocytosis. Cells have transferrin receptors on their surface. 
Two types of transferrin receptors are known, transferrin receptors 1 and 2 (TfR1 and 
TfR2) (Kawabata et al., 1999). TfR1 is present in all cells, while TfR2 is present in 
hepatocytes and small intestinal crypt cells. The function of TfR1 is to facilitate 
uptake of transferrin into cells, whileTfR2 functions as an iron sensor. Holo-
transferrin binds to its receptor and is endocytosed. The early endosome, thus formed, 
is acidified by Na
+-
H
+
-ATPase, which pumps H
+
 into the endosome. This lowering of 
pH causes a conformational change in the transferrin, resulting in dissociation of ferric 
iron from transferrin (Dautry-Varsat et al., 1983). The ferric iron is converted to 
ferrous form by an endosomalreductase - six transmembrane epithelial antigen of 
prostate 3 (STEAP3) (Ohgami et al., 2005). The ferrous iron is then transported out of 
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the endosome into the cytosol by DMT1(Fleming et al., 1999). Thus, DMT 1 is not 
only involved in the absorption of ferrous iron from the intestinal lumen, but it is also 
essential for the transport of ferrous iron from the endosome into the cytosol after 
erythrophagocytosis(Hentze et al., 2010). The iron is then either utilised by the cell or 
stored in ferritin. The apo-transferrin and the transferrin receptor are recycled back to 
the cell surface, where the apo-transferrin dissociates from its receptor and re-enters 
the circulation (Dautry-Varsat et al., 1983). In physiological states, the uptake of 
transferrin-bound iron by TfR1-mediated endocytosis is the major route of iron uptake 
in cells (Hentze et al., 2010). The cytoplasmic labile iron pool (LIP) is used by 
erythroid cells for synthesis of heme or iron-sulphur clusters, or stored as ferritin in 
the case of other cells. 
In iron-overloaded states, there is an increase in circulating levels of non- transferrin 
bound iron (NTBI). The exact mechanism by which NTBI is formed is not clearly 
understood. It has been proposed that it may involve one or more ferri-reductases on 
the surface of cells (Ji and Kosman, 2015). NTBI is taken up into cells by ZRT/ IRT-
like proteins (ZIPs), namely ZIP14 andZIP18 (Jenkitkasemwong et al., 2012; Liuzzi et 
al., 2006). After uptake, the iron enters the labile iron pool and follows the same fate 
as iron from the transferrin cycle.  
 
Ferritin 
Excess iron in the intracellular labile iron pool is sequestered in ferritin (Arosio and 
Levi, 2010). The ferritin molecule is a hetero-polymer of 24 subunits, which form a 
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hollow space in the centre. The subunits are composed of heavy (H) and light (L) 
chains. The ferrioxidase activity of H-ferritin enables it to take up ferrous form and 
store it in its ferric form, which is then attached to the glutamyl group of L-ferritin 
(Arosio and Levi, 2010). Each ferritin molecule can store up to ~ 4500 iron atoms in 
the form of non-mineralized ferric hydrate iron (Arosio and Levi, 2010). The transport 
of iron into ferritin is carried out by ribonucleoproteins known as poly(rC)-binding 
proteins 1-4 (PCBP 1-4), which act as chaperones (Lane et al., 2015). The iron in 
ferritin can be mobilized in times of cellular need (Saito, 2014). 
Ferritin is found in circulation in small quantities. The source of this is not clear. 
Ferritin in blood is chiefly made up of L-chains, which are glycated and poor in iron 
content(Santambrogio et al., 1996). Serum ferritin levels reflect the body’s iron stores 
(Lipschitz et al., 1974); levels increase in iron-overloaded states. However, serum 
ferritin is also an acute phase reactant. Its levels are raised in response to 
inflammation. Hence, serum ferritin is not a reliable marker of iron overload in the 
presence of inflammation (Lipschitz et al., 1974). 
 
Regulation of intracellular iron homeostasis: IRE/IRP system (Figure 2) 
Intracellular iron homeostasis is regulated by processes that involve post-
transcriptional changes and by alterations in  the stability of mRNA (Hentze et al., 
2010). The mRNA for iron-related proteins contains hairpin loop-like domains in the 
5’ or 3’untranslated region (UTR). These are known as iron-responsive elements 
(IRE)(Hentze et al., 2010). IREs contain binding sites for iron-regulatory proteins 
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(IRP). There are two types of IRPs- IRP1 and IRP2. They are orthologs, which have 
the same function but are regulated in different ways. IRPs are RNA-binding proteins. 
They interact with iron-responsive elements (IREs) in the 5’ or 3’ UTR regions of the 
target mRNA. On binding, they either stabilize or destabilize the mRNA. This 
outcome is dependent on the location of IRE on the mRNA (Hentze et al., 2010). If 
the IRE is on the 5’ end, then the binding of IRP will lead to inhibition of translation. 
Studies have shown that ferritin (H and L chain), ferroportin,  erythroid ALA synthase 
(ALAS2), mitochondrial aconitase and hypoxia-inducible factor-2α (HIF-2α) have 
IREs in the 5’ end (Anderson et al., 2009; Leibold and Munro, 1988; Rouault, 2005; 
Zheng et al., 1994; Pantopoulos, 2004). 
If the IRE is on the 3’ end, binding of IRP will result in stabilization of mRNA, 
thereby promoting translation. IREs on the mRNA for transferrin receptor1 (TfR1) 
and DMT1are at its 3’ end (Mackenzie et al., 2008). Binding of IRP to the 3’ end of 
mRNA results in increased translation of transferrin TfR1and DMT1. 
Iron-regulatory proteins are induced when iron levels are low and they bind to mRNA. 
When iron levels are high, iron-sulphur clusters are formed, which binds to IRP and 
prevent their binding to IREs. The IRPs then undergo ubiquitination and proteosomal 
degradation (Hentze et al., 2010). When cellular iron is low, the iron-sulphur clusters 
are not formed and the IRPs are free to bind to the IREs. The overall effect is 
decreased utilization and storage of iron, with increased cellular uptake of iron 
(Hentze et al., 2010). 
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Figure 2: Regulation of intracellular iron levels 
Source: Hentze, M.W., Muckenthaler, M.U., Galy, B., and Camaschella, C. (2010). Two to Tango: Regulation 
of Mammalian Iron Metabolism. Cell 142, 24–38. 
Systemic iron homeostasis 
As mentioned earlier, there is no regulated mechanism for excretion of iron from the 
body. Systemic iron homeostasis is thus tightly regulated at the level of intestinal 
absorption. Hepcidin is the central regulator of the processes involved(Hentze et al., 
2010).It is a peptide with anti-microbial properties, synthesized in the liver as a pro-
hormone. A pro-hormone convertase, furin, cleaves the pro-hormone to form 
hepcidin, which contains 25 amino acids (Valore and Ganz, 2008). When first 
discovered, it was called liver-expressed anti-microbial peptide (LEAP 1) (Krause et 
al., 2010). It was later named hepcidin(Park et al., 2001). In circulation, it is bound to 
  
13 
 
α2-macroglobulin(Peslova et al., 2009). It either undergoes excretion via the kidneys 
or degradation, along with ferroportin (as described below) (Hentze et al., 2010). 
The link between hepcidin and iron metabolism was initially unknown. Many studies 
have provided much evidence of links between the two. Hepcidin expression was 
found to be increased in iron-loaded mice (Pigeon et al., 2001). A complete defect in 
expression of hepcidin and associated tissue iron overload were observed in mice in 
which upstream regulatory factor (USF) had been knocked out. Severe iron-deficiency 
anemia was observed in transgenic mice with hepcidin over-expression (Nicolas et al., 
2002).  
Hepcidin has been shown to bind to ferroportin, present in enterocytes, macrophages 
and syncytiotrophoblastsin the placenta (Abboud and Haile, 2000; Donovan et al., 
2005; McKie et al., 2000). This causes its internalization and subsequent degradation 
(Nemeth et al., 2004b). Low hepcidin levels have been shown to be associated with 
increased expression of ferroportin(Viatte et al., 2005).  
 
Regulation of hepcidin synthesis 
Hepcidin synthesis is regulated at the level of transcription, and is influenced by 
numerous factors such iron status, erythroid activity, hypoxia and inflammation. It is 
negatively regulated by low iron levels and increased erythropoiesis. The resultant 
decreases in hepcidinincreases iron absorption from the gut and recycling from 
macrophages. Positive regulators include increased iron levels and inflammation 
(Hentze et al., 2010). Hepcidin is, in fact, a type 2 acute phase protein (Nemeth et al., 
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2003). Inflammation causes upregulation of the transcription of hepcidin, via 
cytokines such as IL-6. This results in decreased iron absorption and promotes 
sequestration of iron in macrophages (Nemeth et al., 2004). 
A. Regulation by iron levels 
Two main signalling pathways are involved in regulation of hepcidin synthesis by 
circulating iron levels.  
a. Hfe-TfR2 (HFE-transferrin receptor 2) pathway  
b. HJV-BMP (hemojuvelin–bone morphogenic protein) pathway  
 
a. Hfe-TfR2 signalling 
Current knowledge of the role of the Hfe-TfR2 pathway in regulation of iron 
homeostasis is based on observations of various mutated membrane proteins (HFE, 
HJV and TfR2) in hereditary hemochromatosis. Hfe and transferrin receptor-2 are 
transmembrane proteins in hepatocytes. Mutations of these proteins were observed in 
patients with hereditary hemochromatosis (Feder et al., 1996; Roetto et al., 2002). In 
such patients, it was found that, despite the iron overload, they were found to have low 
hepcidin levels. The iron overload was held  to be due to increased iron absorption in 
the presence of low levels of hepcidin(Bridle et al., 2003; Nemeth et al., 2005; 
Papanikolaou et al., 2004). Nicolas et al (2002) showed that crossing Hfe
-/-
 and 
hepcidin over-expressing transgenic mice resulted in mice that constitutively 
expressed hepcidin, thereby preventing  iron overload, an observation that was in 
contrast to what is seen in Hfe
-/- 
mice.  
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Hfe is a transmembrane protein expressed in hepatocytes (Zhang et al., 2004). 
Structurally, it resembles the class I major histocompatibility complex (MHC), with 
α1, α2 and α3 chains, associated with β2-microglobulin(Li et al., 2016). Transferrin 
receptor-1(TfR-1) is present in most cells and enables iron uptake, via holo-
transferrin. TfR-1 has binding sites for both Hfe and holo-transferrin; these sites 
overlap each other. It can only bind either Hfe or holo-transferrin at a time (Feder et 
al., 1998), with a greater affinity for holo-transferrin. Hence, binding of holo-
transferrin to TfR1 results in dissociation of Hfe from TfR-1. In keeping with this, 
increased concentration of holo-transferrin was found to displace Hfe from TfR1(Gao 
et al., 2010).TfR-2 is also a transmembrane protein; it is involved in sensing iron 
levels (Kawabata et al., 1999). Unlike TfR-1, TfR-2 can simultaneously bind Hfe and 
holo-transferrin (Chen et al., 2007).  
In order to study the binding affinity of TfR1 for Hfe, Schmidtt et al., (2008) 
engineered mouse models with TfR1 mutations. Mutations in TfR1, which produced 
an increased affinity for Hfe, resulted in decreased hepcidin levels and subsequent 
iron overload, as seen in hemochromatosis. On the other hand, mutations of TfR1 that 
produced decreased binding affinity for Hfe resulted in increased hepcidin levels and 
iron deficiency (Schmidt et al., 2008). 
b. HJV-BMP (hemojuvelin–bone morphogenic protein) pathway 
Bone morphogenic proteins (BMP) belong to the transforming growth factor β(TGF-
β) family. They are involved in cell proliferation, differentiation and cell signalling. 
Binding of BMP to its receptor on the cell membrane occurs with the aid of a co-
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receptor hemojevulin(HJV). The binding causes dimerization of type I and II BMP 
receptors (serine/threonine kinase), (Xia et al., 2008). This induces phosphorylation of 
receptor-regulated R-SMAD. This, in turn, results in R-SMAD forming a complex 
with SMAD4, which induces  the transcription of hepcidin by binding to its promoter 
(Shi and Massagué, 2003). Many types of BMP proteins have been identified. Of 
these, BMP-6 is the main ligand for the HJV-BMP pathway in the liver (Enns et al., 
2013). Matripase-2,which is a transmembrane serine protease encoded by the 
TMPRSS6gene, is expressed in the cell membrane of hepatocytes (Velasco et al., 
2002). Mutations in the TMPRSS6 gene resulted in an iron-refractory iron-deficiency 
anaemia (IRIDA) (Finberg et al., 2008). Patients with this mutation also had high 
hepcidin levels. It has also been shown that TMPRSS6 gene expression was increased 
in iron-deficiency anaemia and hypoxia (Talbot et al., 2011). Matripase-2 cleaves the 
membrane-bound HJV. Since HJV acts as a co- receptor for BMP, its cleavage 
inhibits hepcidin transcription via the BMP/SMAD pathway (Silvestri et al., 2008). 
Iron and BMP-6, which induce hepcidin, have beenshown to increase expression of 
matriptase. These findings suggest that matriptase 2 may be involved in fine-tuning of 
hepcidin synthesis, by preventing prolonged up- regulation of hepcidin(Meynard et 
al., 2011). 
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Figure 4: Regulation of hepcidin by systemic iron availability 
 
 
Source: Adapted from Hentze, M.W., Muckenthaler, M.U., Galy, B., and Camaschella, C. (2010). Two to 
Tango: Regulation of Mammalian Iron Metabolism. Cell 142, 24–38. 
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Figure 5: Regulation of hepcidin by erythroid signalling 
 
 
Source: Adapted from Hentze, M.W., Muckenthaler, M.U., Galy, B., and Camaschella, C. (2010). Two to 
Tango: Regulation of Mammalian Iron Metabolism. Cell 142, 24–38. 
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Figure 6: Regulation of hepcidin by inflammation 
 
 
 
Source: Adapted from Hentze, M.W., Muckenthaler, M.U., Galy, B., andCamaschella, C. (2010). Two to 
Tango: Regulation of Mammalian Iron Metabolism. Cell 142, 24–38. 
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B. Regulation by erythroid signals 
Erythropoiesis requires iron. Erythropoietin, produced in the liver and kidneys, is the 
major hormone involved in the process. Increased erythropoietin levels are seen in 
anemic and hypoxic states. Studies in healthy volunteers have shown that 
administration of erythropoietin resulted in decreased hepcidin levels (Robach et al., 
2009). Hepcidin expression was found to be suppressed in participants who underwent 
phlebotomy(which increased erythropoiesis)(Ashby et al., 2010). During 
erythropoiesis, various erythroid factors are released from the bone marrow. These 
include growth differentiation factor 15(GDF15), twisted gastrulation factor (TWSG1) 
and erythroferrone (ERFE). Increased levels of GDF15 have been reported in 
thalassemic patients (Tanno et al, 2007). In thalassemic mice models, TWSG1 and 
ERFE were found to be increased (Mirciov et al., 2017).These observations were 
associated with low hepcidin levels. It has been postulated that these erythroid factors 
act to downregulatehepcidin synthesis, by inhibiting the HJV/BMP pathway (Tanno 
and Miller, 2010; Kautz and Nemeth, 2014).  
 
C. Regulation by inflammation 
Hepcidin is an acute phase reactant (Nemeth et al., 2003). IL-1 and IL-6 increase the 
expression of hepcidin(Nemeth et al., 2004). Such inflammation-induced upregulation 
of hepcidin results in decreased serum iron levels, due to sequestration of iron in 
macrophages and also due to decreased intestinal absorption. IL-6 acts through the 
Janus kinase/ signal transducer and activator of transcription (JAK/STAT) pathway 
and increases hepcidnin transcription (Wrighting and Andrews, 2006). Cross-talk has 
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been shown to occur between interleukin-mediated upregulation of hepcidin(via 
theJAK/STAT pathway)and the BMP/HJV/SMAD pathway via SMAD4 (Wang et al., 
2005). 
 
PREGNANCY 
Pregnancy, a normal physiological process, extends over a period of 280 days or 40 
weeks, counting from a woman’s last menstrual period to child birth. The 40-week 
period is divided into first, second and third trimesters, with each trimester comprising 
a period of 13 weeks (Hill and Pickinpaugh, 2008). 
 
Pregnancy and iron metabolism 
The body undergoes several physiological changes during pregnancy, in order to meet 
the needs of the growing fetus(Hill and Pickinpaugh, 2008).The body’s requirement 
for iron is increased in pregnancy, as it is essential for development of the placenta, 
the growing fetus, to maintain RBC mass and to compensate for blood loss during 
delivery (Koenig et al., 2014).  
The placenta is vital for gas exchange and for nutrient delivery to the fetus. Iron 
deficiency during pregnancy can result in preterm birth and low birth weight. This is 
due to the various pathological processes that occur as a result ofiron deficiency 
(Allen, 2000). Hypoxia is known to initiate the production of corticotrophin-releasing 
hormone (CRH), which in turn, leads to cortisol secretion by the fetus that can cause 
preterm delivery (Gülmezoglu et al., 1996). Iron deficiency has been reported to leads 
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to poor immune response, which results in, increased susceptibility to infection 
causing spontaneous preterm birth (Bhaskaram, 2001). 
 
Placental transfer of iron 
In maternal circulation, iron bound to transferrin (Tf) is taken up by the fetusvia TfR1, 
found in the syncytiotrophoblasts lining the placenta on the maternal side (Kawabata 
et al., 1999). On binding to its receptor in the placenta, the Tf-TfR1 complex is taken 
up by endocytosis and a vesicle is formed in the cytosol. Acidification of the vesicle 
follows. The low pH produced causes dissociation of iron from transferrin (Harris et 
al., 1999). The iron from the vesicle leaves via DMT1on the endosomal membrane 
and is used for cellular needs. If in excess of cellular requirements, iron taken up is 
stored as ferritin or released into the fetal circulation via ferroportin on the basolateral 
side of the placental syncytiotrophoblast(Abboud and Haile, 2000; Harris, 1992). 
Ferrous iron thus released is converted to its ferric form by a ferroxidase(Chen et al., 
2010). 
 
Hepcidin in pregnancy 
During pregnancy, maternal hepcidin levels are determined by the maternal iron status 
and fetal demands (Koenig et al., 2014). Studies have shown that hepcidin levels are 
low in the third trimester, when there is increased transfer of maternal iron to the 
fetus(Gyarmati et al., 2011; Dao et al., 2013). Some studies have shown correlation 
between maternal hepcidin levels and markers of iron status (Schulze et al., 2008) 
(Rehu et al., 2010;van Santen et al., 2013).  
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A meta-analysis on hepcidin and its role in pregnancy included 10 human and 6 
animal studies (Koenig et al., 2014). The human studies comprised both cross-
sectional and longitudinal studies, mostly involving healthy pregnancies with few 
complications. Hepcidin levels have been shown to be lower in pregnant women 
compared to non-pregnant healthywomen(Rehu et al., 2010b). Lowest levels of 
hepcidin have been reported during the third trimester. This  correlates with the high 
uptake of iron from the maternal to the fetal side (Gyarmati et al., 2011b; Finkenstedt 
et al., 2012; van Santen et al., 2013b; Dao et al., 2013). Maternal hepcidin levels have 
been shown to correlate with markers of iron status (Schulze et al., 2008; Rehu et al., 
2010c; van Santen et al., 2013b).In uncomplicated pregnancies, it was shown that 
maternal hepcidin levels during gestation did not correlate with inflammatory markers 
(Schulze et al., 2008; van Santen et al., 2013b). However, in the setting of obesity(Dao 
et al., 2013) or preeclampsia (Toldi et al., 2010), serum hepcidin levels were found to 
correlate with levels of C-reactive protein (CRP), an inflammatory marker.  
 
Gestational diabetes mellitus (GDM) 
Defects in insulin production or insulin action or both lead to diabetes mellitus 
(Alberti and Zimmet, 1998). Globally, about 422 million people are estimated to have 
diabetes mellitus, with the number predicted to increase to 592 million people by 
2030. India has the world’s second largest diabetic population with about 62 million 
diabetics (Anjana et al., 2011). 
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Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed in the second or 
third trimester of pregnancy that is not clearly either type 1 or type 2 diabetes (ADA, 
2016). The prevalence of GDM in India has been estimated to be between 3%-21% 
(Kaveeshwar and Cornwall, 2014; Zhu and Zhang, 2016). The large variation in these 
prevalence figures has been suggested to be due to the use of different diagnostic 
criteria, differences in lifestyles and food habits of the subjects, etc(Rajput et al., 
2013). In Tamil Nadu, the prevalence has been estimated to about 13.8% [urban-
17.8%; semiurban-13.8%; rural-9.9%] (Anjana et al., 2011). 
The screening of GDM is usually done between 24 to 28 weeks of gestation (Sacks et 
al., 2012). One of the most commonly used criteria to diagnose GDM is 
InternationalAssociation of the Diabetes and Pregnancy Study Groups 
(IADPSG)criteria (ADA, 2016); these comprise a fasting plasma glucose levels equal 
to or greater than 92 mg/dL or a 1-hour (post oral glucose load of 75 g) plasma 
glucose value equal to or greater than 180 mg/dL or a 2-hour (post oral glucose load) 
plasma glucose value equal or greater than 153 mg/dL(ADA, 2016). 
GDM is mainly due to insulin resistance that starts during the second trimester and is 
present through the rest of pregnancy (Zhu and Zhang, 2016). Insulin resistance has 
been attributed mainly to placental hormones and maternal adiposity (Kaaja and 
Rönnemaa, 2008). Human placental lactogen [HPL], human chorionic 
somatomammotropin [HCS], estrogen, progesterone, prolactin and cortisol are 
placental hormones that do not cross the placenta. Higher concentrations of these 
hormones due to increases in placental size in the later weeks of gestation can cause 
increases in insulin resistance (Kaaja and Rönnemaa, 2008; Kühl, 1998). 
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Gestational diabetes mellitus is the most common metabolic disorder during 
pregnancy (Buchanan et al., 2012). It is associated with maternal and fetal 
complications. Though the exact mechanism is not known, iron overload has been 
reported to induce β-cell toxicity and to impair glucose metabolism (Lao et 
al.,2001;Ferrannini, 2000). High iron and low insulin levels have been reported in 
patients with GDM (Kaygusuz et al., 2013). Iron has been reported to be a strong pro-
oxidant that can affect insulin synthesis in the pancreas (Rajpathak et al., 2009). 
The link between iron homeostasis and diabetes mellitus was first noted in patients 
with hemochromatosis, who were found to have a high incidence of diabetes mellitus 
(Fernández-Real et al., 2005; Jiang et al., 2004). Frequent blood donations have been 
shown to decreased risk of developing diabetes mellitus (Fernández-Real et al., 2005; 
Jiang et al., 2004; Swaminathan et al., 2007). Treatment of patients with thalassemia, 
who have iron overload, with iron chelators has decreased the incidence of diabetes 
mellitus in this group (Gamberini et al., 2008)   and also decreased diabetes-related 
vascular complications (Nitenberg et al., 2004).  
 
Serum ferritin is a glycated L-subunit of ferritin that is poor in iron (Wang et al., 
2010). It is elevated in conditions of iron overload. Serum ferritin levels have been 
reported to be elevated in subjects with GDM in studies done in Turkey, Iran, 
Denmark and USA (Derbent et al., 2013; Amiri et al., 2013; Bowers et al., 2016; Chen 
et al., 2006).There are no such published studies from India.  
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THE STUDY 
HYPOTHESIS 
Serum ferritin levels may be increased in Indian women with gestational diabetes 
mellitus (GDM).  
 
OBJECTIVES OF THE STUDY 
a. To estimate serum ferritin in subjects with and without GDM 
b. To estimate various iron-related parameters in subjects with and without GDM 
c. To compare the above parameters in those with and without GDM 
d. To determine the outcome of pregnancy in subjects with and without GDM and 
correlate these with estimated parameters 
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MATERIALS 
EQUIPMENT USED 
1. Elix and Milli-Q ultrapure water system (Millipore, USA) 
2. -70OC freezer (Thermo Scientific, Massachusetts, USA) 
3. Table-top refrigerated centrifuge (MPW R 350, MPW Poland) 
4. Micro-plate reader (Model 680, Bio-Rad laboratories, Inc., UK) 
CHEMICALS AND REAGENTS USED FOR HEPCIDIN ESTIMATION 
These were obtained from Peninsula Laboratories (San Carlos, USA) and consisted of 
the following: 
1. Lyophilized standard, anti-serum against hepcidin, biotinylated peptide 
2. Enzyme immune-assay buffer, streptavidin-horseradish peroxidase (HRP), 
substrate solution (TMB – 3, 3’, 5, 5’–tetramethylbenzidine solution) and stop 
solution (2N HCl) 
OTHER MATERIALS USED 
1. Plain red vacutainer tubes for blood collection (BD Biosciences, Plymouth, 
UK) 
2. Micro-tubes (Tarson Products Private Limited, Kolkata, India) 
3. Micro-tips (Tarson Products Private Limited, Kolkata, India) 
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METHODS 
The Institutional Review Board (IRB) at Christian Medical College (CMC), Vellore, 
India, approved this study (IRB Min No 10423 dated 05.12.2016) (included as 
Appendix 1). 
SUBJECTS 
Primigravidae, who attended the antenatal clinic of the Community Health and 
Development (CHAD) Hospital in CMC, Vellore, and who were referred for an oral 
glucose tolerance test (OGTT) (75 gm glucose) as part of their routine antenatal 
check-ups, were recruited for this study. The period of recruitment was from January 
2017 to July 2018.The inclusion criteria were as follows: 
Inclusion criteria 
Primigravidae 
a. who gave consent to participate in the study 
b. who had a packed cell volume (PCV) equal to or greater than 33.0% or 
haemoglobin levels equal to or more than 11 g/dL in the first trimester 
c. with serum C-reactive protein (CRP) level less than or equal to 12 mg/L 
(Abbassi-Ghanavati et al., 2009; Nakishbandy and Barawi, 2014) 
Exclusion criteria 
Primigravidae who 
a. declined to give consent to participate in the study 
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b. had PCV less than 33.0% or haemoglobin levels less than 11 g/dL in the first 
trimester 
c. had serum CRP levels greater than or equal to 12 mg/L 
d. were known to have diabetes mellitus or hypertension 
e. had any pregnancy-related complication, such as chronic infective or 
inflammatory states or pregnancy-induced hypertension or preeclampsia or 
multiple gestation 
f.  
INFORMED CONSENT 
When potential participants were identified, based on the inclusion and exclusion 
criteria listed above, the study was explained to them. They were also provided with 
an information sheet printed in English or Tamil, depending on their preference. 
Written informed consent was obtained from each participant. The format for the 
informed consent form and the information sheet used is included as Appendix 2. 
 
CLINICAL AND DEMOGRAPHIC DATA 
Relevant clinical and demographic data were collected, using a proforma (included as 
Appendix 3). Each participant’s date of last menstrual period was used to calculate 
gestational age. The haematocrit (Hct) values were obtained from their hospital 
records. 
Blood pressure was measured in each subject, using an automatic blood pressure 
apparatus. Each woman’s mid-arm circumference was measured, by using a non-
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stretchable measuring tape, at a point midway between the acromion process of the 
left scapula and the olecranon process of the ulna on the same side. 
All the primigravidae had been prescribed ferrous sulphate (150 mg per day) and folic 
acid tablets (2.5 mg per day) from the time of their first antenatal visit, as per National 
Nutritional Anemia Control Programme (NNACP) guidelines (Kumar, 1999). The 
date when iron and folic acid supplements were prescribed was noted from hospital 
records. At the time of recruitment into the present study, they were asked whether 
they had been taking the tablets regularly. Information on outcomes of pregnancy was 
obtained from hospital records and by contacting the subjects by phone. 
 
CALCULATION OF SAMPLE SIZE 
Information from a study by Derbent et al, (2013) was used to calculate sample size. 
To show a difference of 11.45 units of serum ferritin between women with and 
without GDM, with 90% power and 5% level of significance, 22 samples were 
required in each group (standard deviation of 13.37 in women with GDM and 9.66 in 
women without GDM). The details of this calculation are shown below. 
 
 Derbent et al 2013 
Standard deviation in women with 
GDM 
13.37 
Standard deviation in women without 
GDM 
9.66 
Mean difference 11.45 
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Effect size 0.9943 
Alpha error (%) 5 
Power (1- beta) % 90 
1 or 2 sided 2 
Required sample size per group 22 
 
Formula: 
 
Where,  
Zα/2 is 5% level of significance  
Z1-β is the 80% power  
sd = standard deviation  
d = 21.7 (mean change) 
 
SAMPLE COLLECTION  
A blood sample (fasting) (8 ml) was collected from each subject at the time of her 
OGTT. These were collected in plain red BD vacutainer tube, by venepuncture of the 
cubital vein. 
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PROCESSING AND STORAGE OF SAMPLES 
The blood samples obtained were subjected to centrifugation at 2500g for 10 minutes, 
within 2 hours of sample collection. The serum obtained was divided into multiple 
aliquots and stored at -70
O
C till used for analyses. They were thawed on ice, when 
required for estimations of serum ferritin, iron, CRP and hepcidin. 
 
ESTIMATION OF SERUM FERRITIN 
Serum ferritin was measured in Department of Clinical Biochemistry, CMC, Vellore. 
This is a routine test offered by this laboratory. 
Analyzer used 
Siemens, ADVIA, Centaur System, XPi, UK 
Principle of the method (two-site sandwich immunoassay using direct 
chemiluminescence technology) 
In this method, two anti-ferritin antibodies were used. The first antibody, which is a 
monoclonal mouse anti-ferritin antibody in the solid phase, was covalently attached to 
paramagnetic particles. The second antibody was a polyclonal goat anti-ferritin 
antibody linked with acridinium ester. These antibodies were sequentially added to the 
reaction container. They bound to the ferritin present in the sample. On adding a 
substrate (0.1N nitric acid, 0.5% hydrogen peroxide in alkaline medium) that excites 
acridinium, photons were released, which were measured as relative light units (RLU). 
The amount of RLU detected was directly proportional to the amount of ferritin 
present in the sample. 
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ESTIMATION OF SERUM IRON 
Estimation of serum iron was done in the Department of Clinical Biochemistry, CMC, 
Vellore. This is a routine test offered by this laboratory. 
Analyzer used 
Roche Cobas C720 modular analyzer from Roche Diagnostics, Gmbh, Mannheim 
Principle (colorimetric method) 
In the acidic medium provided, ferric iron was released from transferrin. Ascorbate 
was added to reduce ferric iron into ferrous form. Ferrous iron bound with a dye, 
ferrozine, to form a purple coloured complex, which was measured at 560 nm. The 
intensity of the purple colour that developed was directly proportional to the amount 
of iron in the sample. 
 
ESTIMATION OF TOTAL IRON-BINDING CAPACITY (TIBC) 
Estimation of TIBC was done in the Department of Clinical Biochemistry, CMC, 
Vellore. This is a routine test offered by this laboratory. 
Analyzer used 
Roche Cobas C720 modular analyser from Roche Diagnostics, Gmbh, Mannheim 
Principle (colorimetric method) 
To a known amount of reagent solution (consisting of an alkaline buffer, containing 
known concentrations of iron and ferrozine), the serum sample was added. At alkaline 
pH, iron in the reagent binds with unoccupied sites on transferrin, leaving unbound 
iron free. The free iron complexes with ferrozine to give a purple complex, the 
intensity of colour of which was measured at 560 nm. The intensity of the purple 
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colour that developed was directly proportional to the amount of unbound iron. The 
difference between the amount of iron added and the unbound iron was taken to be the 
unbound iron binding capacity (UIBC). The sum of serum iron and UIBC represented 
total iron binding capacity (TIBC). 
 
CALCULATION OF TRANSFERRIN SATURATION 
Transferrin saturation was calculated as the percentage of the ratio of serum iron to 
TIBC, as shown in the formula below: 
Transferrin saturation (%) = (Serum iron/TIBC) x 100 
  
ESTIMATION OF SERUM C-REACTIVE PROTEIN 
Estimations of CRP were done in the Department of Clinical Microbiology, CMC, 
Vellore. This is a routine test offered by this laboratory. 
Analyzer used 
BN Prospec, Siemens, Gmbh, Mannheim, Germany 
Principle (nephelometry) 
Polysterene particles (coated with antibodies against CRP) aggregated with serum 
CRP, when a serum sample was added to the reaction chamber. This aggregation led 
to scattering of light, when light was passed through the reaction chamber. The 
amount of light scattered was measured by a sensor and was directly proportional to 
the amount of CRP present in the sample. 
 
 
  
35 
 
ESTIMATION OF SERUM HEPCIDIN 
ELISA kit and reagents for hepcidin estimation were purchased from Peninsula 
Laboratories, (San Carlos, USA). 
Principle of the method 
The estimation of hepcidin was based on a competitive immunoassay. Hepcidin in the 
sample competed with a biotinylated tracer to bind to the antibody against hepcidin. 
The amount of biotinylated tracer that bound to the antibody was inversely 
proportional to the amount of hepcidin in the sample.  
 
Source: Product information sheet of the hepcidin kit (Hepcidin-25 [for serum and plasma samples]) Peninsula 
Laboratories (Cat No S-1337) 
 
Components of the kit 
1. 96-well plate 
2. Biotinylated peptide, in the form of a lyophilised powder 
3. Hepcidin peptide (lyophilised powder) (1µg) 
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4. Rabbit antiserum against hepcidin 25(lyophilised powder) 
5. Enzyme immunoassay buffer (50mL) 
6. Standard diluents (peptide-free human serum) (8mL) 
7. Streptavidin horseradish peroxidase (100μL) 
8. Substrate solution (TMB 3,3’,5,5’-tetramethyl benzidine)(11mL of TMB and 
hydrogen peroxide) 
9. 2N HCl (hydrochloric acid) (15mL) (stop solution) 
As per manufacturer’s instructions, enzyme immunoassay buffer, streptavidin-HRP 
substrate and stop solution were stored in a refrigerator (2 to 8
o
C). The diluents for the 
standard, lyophilised standard, anti-serum and biotinylated peptide were stored at -
20
o
C. The stability of these reagents was 1 year, under conditions listed above. 
Preparation of reagents 
The unopened kit and reagents were brought to room temperature, before preparation 
of working reagents and samples. 
1. Stock standard: To 1μg of lyophilised standard, 1mL of standard diluent was 
added and mixed thoroughly, using a vortex mixer. 
 
Standard ng/mL Range : 0.02 to 25ng/mL 
Stock 1000  
S1 25 Added 5μL stock  + 195μL diluents 
S2 6.25 Added 40μL (S1)+ 40μL diluents 
S3 1.56 Added 40μL (S2)+ 40μL diluents 
S4 0.39 Added 40μL (S3)+ 40μL diluents 
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S5 0.10 Added 40μL (S4)+ 40μL diluents 
S6 0.02 Added 40μL (S5)+ 40μLdiluents 
S0 0.00 120μL diluents 
 
2. Samples: The samples in the study were diluted 1 in 10 (12μL of sample + 108 
μL of standard diluent). Dilutions were carried out to bring the concentration of the 
analyte within the analytical measurement range. 
3. Enzyme immunoassay buffer (EIA buffer):  EIA buffer (50mL) was diluted to 
1000mL, using sterile deionised water (18Mohm).  
4. Anti-serum: To the lyophilised anti-serum powder, 5mL of EIA buffer was 
added and mixed well. 
5. Biotinylated tracer (bt tracer): To the lyophilisedBt-tracer powder, 5mL of EIA 
buffer was added and mixed well. 
6. Streptavidin- HRP: This was diluted 1in 200 with EIA buffer (60 µL of 
streptavidin-HRP made up to 12 mL with EIA buffer), and mixed well. 
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Layout of a 96-well coated micro-well plate for the hepcidin assay 
 1 2 3 4 5 6 7 8 9 10 11 12 
A B B T1 T1 T9 T9 T17 T17 T25 T25 T33 T33 
B S1 S1 T2 T2 T10 T10 T18 T18 T26 T26 T34 T34 
C S2 S2 T3 T3 T11 T11 T19 T19 T27 T27 T35 T35 
D S3 S3 T4 T4 T12 T12 T20 T20 T28 T28 T36 T36 
E S4 S4 T5 T5 T13 T13 T21 T21 T29 T29 T37 T37 
F S5 S5 T6 T6 T14 T14 T22 T22 T30 T30 T38 T38 
G S6 S6 T7 T7 T15 T15 T23 T23 T31 T31 T39 T39 
H S0 S0 T8 T8 T16 T16 T24 T24 T32 T32 T40 T40 
B- blank, S- standard, T- test samples 
Assay procedure 
Step 1: 25μL of antiserum was added to each well; 25μL of EIA buffer was added to 
the blank well. These were incubated for 1hour at room temperature. 
Step 2: 50μL of diluted standard/ sample was added to respective wells. To the blank 
well, 50μL of diluent was added. The plate was incubated for 2hours at room 
temperature. 
Step 3: 25μL of reconstituted Bt-tracer was added to each well.  
Step 4: Using its acetate plate cover (provided with the kit), the microplate was sealed 
and incubated overnight, at 4
o
C in a refrigerator. 
Step 5: The microplate was taken out of the refrigerator the next day and allowed to 
come to room temperature. 
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Step 6: Each well was carefully washed, with 300μL of EIA buffer. This was done 5 
times. 
Step7: 100μL of streptavidin-HRP solution was added to each well. The plate was 
incubated at room temperature for 1hr. 
Step 8: At the end of the incubation, each well was washed with 300μL of EIA buffer. 
This was done 5 times.  
Step 9: 100μL of TMB (substrate solution) was added to each well. The reaction 
mixture was incubated at room temperature for 60mins. 
Step 10: During development of a blue color that ensued, readings of the wells in the 
plate were taken at 650 nm,at 15, 30, 45, and 60 minutes after addition of TMB. 
Step 11: At the end of 60 minutes, 2N HCl (100μL per well) was added to terminate 
the reaction. 
Step 12: Readings were then taken at 450 nm, at 3, 6, and 10 mins after terminating 
the reaction. 
The intensity of colour in each plate was measured as its optical density (OD),using 
the software for the microplate manager of the ELISA plate reader. 
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Image of the microtitre plate after termination of the reaction 
 
All standards and samples were estimated in duplicate; the average of the OD readings 
was used for purposes of calculations. The OD values obtained for the standards were 
used to plot a standard curve, by 4-parameter logistic regression.  A semi-log scale 
was used (on Microsoft Office Excel 2010). The concentrations of standards (ng/mL) 
were plotted on the X-axis and the OD readings on Y-axis. Values for serum hepcidin 
levels were calculated after adjusting for sample dilutions (dilution factor of 10).This 
was done, using four parameter logistic regression analysis, by the following equation: 
 
                                      Y= [(a-d) + {1+ (x/c) b}] + d 
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The values a (maximum value of OD in the standard curve), b (slope), c (point of 
inflection (IC50)), d (minimum value of OD in the standard curve) in the equation 
were used to get the standard curve to fit the data, as closely as possible. 
 
Standard curve of hepcidin 
 
 
 
 
 
The concentration of hepcidin (ng/mL) in each sample was calculated, using the 
following equation: 
 
                                          X=[c*{(x-a)/(d-y)}^(1/b)] 
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DATA ANALYSIS 
Data were analyzed using the Statistical Package for Social Sciences (SPSS), version 
17. The Kolmogorov-Smirnov test was used to check normality of distribution of data. 
The independent student’s t-test was used to analyze data that was normally 
distributed and the Mann-Whitney U test for data that had a skewed distribution. For 
categorical variables, the difference between two groups was analyzed by chi-square 
test. Pearson’s and Spearman’s correlation coefficients were used for correlation 
analysis of normally distributed and skewed data, respectively. In all cases, a p value 
of less than 0.05 was taken to indicate statistical significance. 
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RESULTS 
Eighty two primigravidae were recruited during the period of the study. Of these, 23 
were diagnosed to have GDM (28.04%), based on the results of their OGTT. The 
remaining 59 had normal results for their OGTT (71.95%). Of the 82 recruited, 49 
women (59.75%) delivered their babies in CHAD hospital, 26 (31.70%) delivered in 
other hospitals and 5 (6.07%) delivered in their homes. At the time of analysis, 2 
women (2.43%) were yet to deliver. Two of the women had delivered low-birth 
weight babies (less than 2500 gm); another baby had respiratory distress initially, but 
recovered soon. 
DISTRIBUTION OF DATA 
Data on gestational age at the time of recruitment, values for haematocrit, height, 
duration for which iron and folic acid supplementation were prescribed, serum iron, 
TIBC, CRP, gestational age at delivery, birth weight of the newborns and length of the 
newborns were found to be normally distributed. Data on maternal age, mid-arm 
circumference, weight, body mass index, plasma glucose values, serum ferritin, serum 
hepcidin, transferrin saturation and the APGAR score were found to have skewed 
distributions. 
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Table 1: Clinical characteristics of subjects in the study 
 Controls  
(N = 59) (median 
[IQR] /mean ± 
SD) 
GDM (N = 23) 
(median [IQR] 
/mean ± SD) 
P value 
Age (years) 22 [21-24] 23 [20 - 25] 0.763 
Gestational age at time of 
recruitment (days) 
178.59 ± 23 176.48 ± 27.9 0.75 
Height (cm) 154.44 ± 7 156.91 ± 6.1 0.123 
Weight (kg) 56 [49.4 - 63.5] 62.6 [54 - 734] 0.066 
Mid arm circumference 
(cm) 
25 [23-27.5] 26 [24 - 28] 0.226 
Haematocrit (%) 36 [34.5 - 37] 36 [35.3 - 37.6] 0.377 
Duration for which iron 
supplements had been 
prescribed (days) 
95.74 ± 41 84.22 ±  40.2 0.255 
Body mass index (Kg/m
2
) 22.7 [21.2-25.3] 25.8 [22.4-28.1] 0.090 
 
Data were analysed by Mann-Whitney U test or Student’s t test, as appropriate.  
Maternal ages, gestational ages, height, mid-arm circumference, haematocrit, duration 
for which iron supplements had been prescribed and body mass index were similar in 
the control and GDM groups. When asked about regularity of taking the iron 
supplements, all women said they were compliant. They stated that every morning 
they took the tablet prescribed, on an empty stomach. The weight of women with 
GDM tended to be higher than those without GDM (p= 0.066).  
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Table 2: OGTT resultsin control and GDM subjects 
 Controls 
(N=59) 
(mean ± SD) 
GDM  
(N = 23) 
(mean ± SD) 
P value 
Fasting plasma 
glucose (mg/dL) 
81.93 ± 4.9 92.09 ± 8.4 <0.001 
Plasma glucose after 1 
hr during OGTT 
(mg/dL) 
135.39 ± 25.3  171.96 ± 40.1 <0.001 
Plasma glucose after 2 
hr during OGTT 
(mg/dL) 
117 ± 18.3 149.22 ± 32.2 <0.001 
 
Data were analysed by Mann-Whitney U test or Student’s t test, as appropriate.  
Fasting levels of plasma glucose levels and values at 1 and 2 hours after the glucose 
load were significantly higher in women with GDM than in those without. 
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Table 3: Family history of diabetes mellitus 
3a: 
 
 
 
 
3b: 
Group Family history of diabetes mellitus 
 
Both 
parents 
Father Mother No history 
Controls  
(N=59) 
7 
(11.86%) 
19 
(32.20%) 
6 
(10.16%) 
27 
(45.76%) 
GDM 
(N=23) 
3 
(13.04%) 
9 
(39.13%) 
4 
(17.39%) 
7 
(30.43%) 
 
There was no significant difference between the 2 groups, with regard to a family 
history of diabetes (as assessed by the Chi-square test). 
 
 
 
 
 
Group Family history of diabetes mellitus 
 Absent Present 
Controls 
(N=59) 
27 (45.76%) 32 (54.23%) 
GDM 
(N= 23) 
7 (30.43%) 16 (69.56%) 
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Figure 1: Haematocrit values in control and GDM groups 
 
Data are shown as box and whisker plots, with median and quartiles. 
 
Haematocrit values in the control and GDM groups were similar in both groups 
(p=0.377). 
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Figure 2: Serum iron levels in the control and GDM groups 
 
Data are shown as box and whisker plots, with median and quartiles. 
 
Serum iron levels in the control and GDM groups were similar in both groups  
(p = 0.987). 
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Figure 3: Serum ferritin levels in the control and GDM groups 
 
Data are shown as box and whisker plots, with median and quartiles. 
 
Serum ferritin levels in the control and GDM groups were similar in both groups (p = 
0.59). 
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Figure 4: Serum hepcidin levels in the control and GDM groups 
 
Data are shown as box and whisker plots, with median and quartiles. 
 
Serum hepcidin levels in the control and GDM groups were similar in both groups (p 
= 0.811). 
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Figure 5: Serum TIBC values in the control and GDM groups 
 
Data are shown as mean ± SD. 
 
Serum TIBC values in the control and GDM groups were similar in both groups (p = 
0.167). 
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Figure 6: Serum transferrin saturation levels in the control and GDM groups 
 
Data are shown as box and whisker plots, with median and quartiles. 
 
Serum transferrin saturation levels in the control and GDM groups were similar in 
both groups (p = 1.0). 
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Figure 7: Serum CRP levels in the control and GDM groups 
 
Data are shown as box and whisker plots, with median and quartiles. 
 
Serum CRP levels were not significantly differentin subjects with GDM than those 
without GDM (p = 0.151). 
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Figure 8: Number of days for which iron was prescribedin the control and GDM 
groups 
 
Data are shown as mean ± SD. 
 
The duration for which iron was prescribedwas similar in both groups (p = 0.255). 
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Figure 9: Correlation analysis of serum levels of ferritin and iron 
 
There was no significant correlation between serum levels of ferritin and iron. 
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Figure 10: Correlation analysis of serum levels of ferritin and TIBC 
 
Serum ferritin levels bore a significant negative correlation with serum TIBC values. 
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Figure 11: Correlation analysis of serum ferritin and transferrin saturation 
 
There tended to be a positive correlation between serum ferritin and transferrin 
saturation (p = 0.056). 
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Figure 12: Correlation analysis of serum levels of ferritin and CRP 
 
There was no significant correlation between serum levels of ferritin and CRP. 
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Figure 13: Correlation analysis of serum levels of hepcidin and ferritin 
 
Serum hepcidin levels bore a significant positive correlation with serum ferritin levels. 
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Figure 14: Correlation analysis of serum levels of hepcidin and iron 
 
Serum hepcidin levels bore a significant positive correlation with serum iron levels. 
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Figure 15: Correlation analysis of serum levels of hepcidin and TIBC 
 
Serum hepcidin levels bore a significant negative correlation with values for TIBC. 
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Figure 16: Correlation analysis of serum levels of hepcidin and transferrin 
saturation 
 
Serum hepcidin levels bore a significant positive correlation with transferrin saturation 
levels. 
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Figure 17: Correlation analysis of serum levels of hepcidin and CRP 
 
There was no significant correlation between serum levels of hepcidin and CRP. 
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Table 5: Outcomes of pregnancies of the subjects 
   Controls  
(mean ± SD or 
median [IQR])  
GDM  
(mean ± SD or 
median [IQR]) 
P value 
Gestational ages at delivery 
(days)  
252.64 ± 13.4 258.13 ± 13.1 0.101 
Birth weight of baby (kg)  2.81 [2.6 - 3.2] 2.66 [2.49 - 2.96] 0.088 
APGAR score (out of 15)  14 [13 - 15] 13 [12.5 - 15] 0.535 
Length of the baby (cm)  53 [52 - 56] 54 [52 - 57] 0.389 
 
Data were analysed by Mann-Whitney U test or Student’s t test, as appropriate.  
 
The gestational ages at which delivery occurred, birth weights of the baby, the 
APGAR scores and lengths of the new-born babies were similar in both groups. 
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Table 6: Mode of delivery 
Group Mode of delivery 
 
Normal 
vaginal 
delivery 
Forceps Suction cup LSCS 
Controls 
(N= 57) 
29 
(50.87%) 
3 
(5.26%) 
4 
(7.01%) 
21 
(36.84%) 
GDM 
(N= 23) 
10 
(43.47%) 
2 
(8.69%) 
2 
(8.69%) 
9 
(39.13%) 
 
There was no significant difference between the 2 groups, with regard to modes of 
delivery.  
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SUMMARY OF FINDINGS  
1. Primigravidae, with and without GDM, did not differ with regard to values of 
haematocrit, BMI, serum ferritin, hepcidin, iron, TIBC, transferrin saturation and 
CRP. 
2. Serum ferritin bore a significant positive correlation with serum transferrin 
saturation, and a significant negative correlation with TIBC values. 
3. Serum hepcidin level bore significant positive correlation with serum iron, ferritin 
and transferrin saturation and a significant negative correlation with TIBC values. 
3. The gestational ages at delivery, birth weight of the baby, the APGAR score, and 
length of the new-borns were similar in both groups. 
4. There were no significant difference between the 2 groups, with regard to presence 
of a family history of diabetes mellitus, duration of iron supplementation and modes 
of delivery. 
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DISCUSSION 
In pregnancy, serum ferritin levels have been shown to be lower compared to healthy 
non-pregnant women, reflecting a state of iron deficiency (Adediran et al., 2011; 
Alper et al., 2000). It is, therefore, expected that hepcidin expression would be 
downregulated during pregnancy to meet the additional needs of the growing fetus. 
Serum ferritin and hepcidin levels have been shown to decline in pregnancy, with 
levels being lowest in the third trimester (Adediran et al., 2011; Alper et al., 2000; 
Dao et al., 2013; Finkenstedt et al., 2012; Gyarmati et al., 2011; van Santen et al., 
2013). Maternal serum ferritin levels have been shown to peak in the second trimester 
and decline thereafter (Larsson et al., 2008; Xiao et al., 2002). 
Studies have shown that maternal serum hepcidin levels are significantly lower than 
fetal cord blood hepcidin levels (Rehu et al., 2010; van Santen et al., 2013). However, 
maternal hepcidin levels have been shown to negatively correlate with serum iron and 
transferrin saturation in cord blood, suggesting increased transfer of iron to the fetus 
(Dao et al., 2013; Koenig et al., 2014).Koenig et al. (2014) published a meta-analysis 
of studies on hepcidin in pregnancy, reviewing 10 human and 6 animal studies. 
Among the human studies, 4 were longitudinal and 6 were cross-sectional. These 
studies varied in their sample sizes, the time points (during pregnancy, at delivery or 
postpartum) at which samples were collected, the subjects studied (healthy pregnant 
subjects, with placental malarial infection, preeclamptic subjects etc) and type of 
samples (serum, plasma, cord blood or urine) used for estimation of hepcidin. 
Estimations of serum hepcidin in these studies were done by different methods such as 
enzyme-linked immune-sorbent assay (ELISA), mass spectrometry and cation-
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exchange chromatography. It is difficult to make direct comparison of serum levels of 
hepcidin levels across these studies, as measurements were carried usingdifferent 
methods of assay. There is no established reference interval for serum hepcidin across 
the trimesters of pregnancy. The small number of studies in this area, variations in 
methods of estimation and lack of an established reference interval make it difficult to 
directly compare the results of above studies (Koenig et al., 2014). 
Studies have shown that serum ferritin and hepcidin levels were elevated in patients 
with type 2 diabetes mellitus (Altamura et al., 2017; Andrews et al., 2015; Martinelli 
et al., 2012). Increased serum ferritin levels in pregnant women have been reported to 
be a significant risk factor for gestational diabetes mellitus (Amiri et al., 2013; Chen et 
al., 2006; Javadian et al., 2014; Kataria et al., 2018; Lao et al., 2001). The study by 
Derbent et al. (2013), carried out in a Turkish population, reported significantly 
elevated serum ferritin, hepcidin and iron levels in women with GDM, compared to 
women with impaired glucose tolerance (IGT) and pregnant women with normal 
glucose tolerance. 
In the present study, serum levels of ferritin, hepcidin, iron, TIBC values and 
percentage of transferrin saturation, were similar in women with and without GDM. 
The above findings are in contrast to those of Derbent et al (2013).  There are some 
similarities and a number of important differences between the findings and 
methodologies in the 2 studies. These are summarized in the tables below. 
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Similarities between the present study and that by Derbent et al (2013) 
Feature  Present study  Study by Derbent et al 
(2013) 
Gestational agewhenblood 
was taken for estimations 
of parameters of  interest  
24-28 weeks  24-28 weeks  
Haematocrit values  Similar in those with and 
without GDM.  
Similar in those with and 
without GDM.  
 
Differences between the present study and that by Derbent et al (2013) 
Feature  Present study  Study by Derbent et  al 
(2013) 
Sample size    
 
82 in total (23 with GDM 
and 59 without GDM) 
149 in total (30 with GDM, 
72 without GDM and 47 
with impaired glucose 
tolerance) 
Gravida of subjects 
in the study  
  
 
Subjects with and without 
GDM were all primigravidae. 
Women with GDM were 
multipararous, while those 
without GDM were 
primigravidae.  
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Feature  Present study  Study by Derbent et  al 
(2013) 
Ages of subjects in 
the study  
  
 
Ages of women with and 
without GDM were similar 
Women with GDM were 
significantly older than 
women without GDM 
BMI of subjects in the 
study  
  
 
BMI and mid-arm 
circumference were found to 
be similar in both groups of 
women. 
Women with GDM had 
significantly higher BMI 
values than women 
without GDM. 
Iron and folic acid 
supplements  
  
 
All subjects were on iron and 
folic acid supplements 
None were on iron or folic 
acid supplements 
Blood sample used for 
measurement of serum 
levels of ferritin, hepcidin 
and marker of iron stores 
Fasting blood sample   
 
Blood samples collected 
were in the non-fasting 
state.  
Assay and instrument used 
for estimation of serum 
ferritin levels 
Chemiluminescence assay, 
Siemens, ADVIA, Centaur 
System, XPi, UK 
Electro-
chemiluminescence assay, 
E170, Roche, Germany  
ELISA kit used for 
estimation of serum 
hepcidn 
Peninsula laboratories, USA  DRG Instruments, 
 Marburg, Germany  
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Feature  Present study  Study by Derbent et  al 
(2013) 
Diagnosis of GDM 
made by  
 
  
 
OGTT using 75 gm of oral 
glucose load 
Glucose challenge test 
(GCT) (50 gm of glucose 
load), followed by 
anOGTT (100 gm of 
glucose load), for those 
who tested positive on the 
GCT.  
Diagnostic criteria 
used for GDM  
  
 
At least 1 abnormal value of 
plasma glucose for fasting, 1 
hour or 2 hours samples, 
after a 75 gm glucose load, as 
per criteria of the 
International 
Association of the Diabetes 
and Pregnancy Study Groups 
(IADPSG)(ADA, 2016). 
At least 2 abnormal values 
of plasma glucose for 
fasting, 1 hour, 2 hours and 
3 hours samples, after a 
100 gm glucose load 
(modified National 
Diabetes Data Group 
[NDDG] criteria) 
(Carpenter and Coustan, 
1982) 
Serum ferritin levels    
 
Serum ferritin levels were 
similar in those with GDM 
and without GDM. 
Serum ferritin levels were 
significantly higher in 
those with GDM than in 
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those without GDM. 
Feature  Present study  Study by Derbent et  al 
(2013) 
Serum hepcidin levels    
 
Serum hepcidin levels were 
similar in those with GDM 
and without GDM. 
Serum hepcidin levels 
were significantly higher 
in those with GDM than in 
those without GDM. 
Serum iron levels    
 
Serum iron levels were 
similar in those with GDM 
and without GDM. 
Serum iron levels were 
significantly higher in 
those with GDM than in 
those without GDM. 
Serum CRP levels    
 
Serum CRP levels were 
similar in those with and 
without GDM. 
Serum CRP levels were 
significantly higher in 
those with GDM than in 
those without GDM. 
 
The above table clearly shows that the subjects and methodologies in the present study 
and that by Derbent et al (2013) are different in numerous ways. This may account for 
many of the differences seen in the results of the 2 studies. The differences in the 
methodologies used in the 2 studies, thus, make it difficult to make direct comparisons 
of the data obtained in them.  
  
73 
 
The present study shows that serum ferritin levels were similar in women with and 
without GDM. It has been reported that increased levels of serum ferritin in pregnant 
women were associated with increased risk of gestational diabetes mellitus (Chen et 
al., 2006; Kataria et al., 2018). However, the present study does not show this 
association. This difference could be due to the fact that in those earlier studies 
multiparous women were included in the GDM group, different glucose loads were 
used for the GTT and the BMI were significantly higher in women with GDM. 
Maternal serum ferritin levels showed positive correlation with percentage of 
transferrin saturation and a significant negative correlation with values for TIBC. 
These findings are in agreement with other studies that showed that maternal serum 
ferritin levels correlated significantly with percentage of transferrin saturation and 
TIBC (Amiri et al., 2013; Kataria et al., 2018; Raza et al., 2011). 
In the present study, maternal serum hepcidin levels showed a significant positive 
correlation with serum levels of ferritin, iron, percentage of transferrin saturation and 
a significant negative correlation with TIBC. These findings are in agreement with 
other studies that showed that maternal hepcidin levels correlated significantly with 
markers of maternal iron status (Finkenstedt et al., 2012; Rehu et al., 2010; van Santen 
et al., 2013). 
In the present study, body mass index (BMI) was not significantly different between 
women with and without GDM. However, the calculation of BMI in pregnancy is 
generally not held to be reliable (Nuttall, 2015; Widen and Gallagher, 2014). Hence, 
the mid-arm circumference (MAC) of each subject was also used in the present study. 
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Studies have been used MAC as an indicator of obesity (Fakier et al., 2017; Okereke 
et al., 2013). The MAC of the subjects in 2 groups in the present study wassimilar. 
MAC hasalso been reported to be similar in pregnant women, irrespective of their 
taking iron supplements(Hedengran et al., 2016). This parameter also did not differ 
between pregnant women with favourable and favourableoutcomesof pregnancy (van 
Santen et al., 2013; Schulze et al., 2008). 
Iron-related parameters in blood are known to be affected by iron supplements 
(Alizadeh and Salehi, 2016; van Santen et al., 2014). Hence, these parameters in the 
present study should have been estimated under supplement-free conditions. However, 
it is mandatory to supplement iron and folic acid in pregnant women, as per national 
and international guidelines (Kumar, 1999; Peña-Rosas et al., 2012). It would have 
been unethical to have withheld iron and folic acid supplements from the pregnant 
women in the present study. Therefore, women in both control and GDM groups 
received iron and folic acid supplements. It is hoped that intake of iron in both groups 
would have controlled for the possible confounding effects of iron on the parameters 
of interest, namely, serum levels of ferritin, hepcidin, iron, transferrin saturation 
percentage and TIBC values. No significant differences were observed in values of 
these parameters between the 2 groups. Serum hepcidin levels have been shown to 
increase in response to oral iron (Moretti et al., 2015).  However, interestingly, it has 
been reported in a recent study that serum hepcidin levels were lower in pregnant 
women who took adequate iron supplements (Friedrisch and Friedrisch, 2017). The 
exact basis of this observation is not clear.  
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Pregnancy is a pro-inflammatory state. Pregnant women have been shown to have 
elevations in  inflammatory markers, compared to healthy non-pregnant women 
(Nemeth et al., 2003). In the study by Derbent et al (2013), serum C-reactive protein 
(CRP) levels were significantly higher in women with GDM, than women without 
GDM. However, the present study has shown that serum CRP levels were similar in 2 
groups. Factors that may contribute to this difference include the facts that women 
with GDM in the study by Derbent et al (2013) were older than the control subjects, 
were multiparous (while those in the control group wereprimigravidae) and had higher 
values for BMI than control subjects. 
In present study, the various parameters related to outcomes of pregnancy, such as 
gestational age at delivery, birth weight of the newborns, the APGAR score and the 
length of the newborns were similar in 2 groups. Otherstudies have shown that there 
were significant adverse outcomes of pregnancies in women with GDM 
(Boriboonhirunsarn et al., 2006; Mayor, 2017; Wendland et al., 2012). The women 
with GDM in the above studies were older than the subjects in the present study and 
were also obese. These factors may have influenced the outcomes of their 
pregnancies. The data for the women who did not deliver in CHAD is not as reliable 
as that obtained from the medical records in CHAD, as the former were obtained by 
phone interviews with the women some weeks/months after they had delivered. 
Hence, it is not possible to draw definitive conclusions from these observations.  
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CONCLUSION 
There were no significant differences in levels of serum ferritin and other iron-related 
parameters in women with and without GDM. Hence, based on the data in this study, 
it does not appear that increased serum ferritin levels may be useful as a marker for 
development of GDM.  
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LIMITATIONS OF THE STUDY 
1. One of the secondary objectives of the study was to follow up the subjects to 
determine outcomes of pregnancies. However, some of them were yet to deliver at the 
time of submission of this thesis. Hence, it has not been possible to document all these 
outcomes to complete the comparisons between the 2 groups.  
 
2. It was not possible to estimate additional parameters linked to diabetes mellitus and 
body iron status (such as serum insulin, complete blood counts, and serum levels of 
soluble transferrin receptor), due to financial constraints. These parameters may have 
provided additional useful information.  
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APPENDIX 4: MASTER DATA SHEET 
 
Category Fasting 
plasma 
glucose 
(mg/dL) 
One hr 
post 
OGTT 
plasma 
glucose 
(mg/dL) 
Two hr 
post 
OGTT 
plasma 
glucose 
(mg/dL) 
Age 
(years) 
Gestational 
age at 
recruitment 
(days) 
Hct 
(%) 
MAC 
(cm) 
Duration 
for which 
iron was 
prescribed 
(days) 
Ferritin 
(ng/mL) 
Iron 
(µg/dL) 
UIBC 
(µg/dL) 
TIBC 
(µg/dL) 
Transferrin 
saturation 
(%) 
CRP 
(mg/L) 
Hepcidin 
(ng/mL) 
Control 74 112 107 23 196 35.5 28 157 33.3 87 416 503 17 8 11.63 
Control 76 112 118 26 179 34.8 26 0 30.3 71 346 417 17 6 22.33 
Control 81 144 116 18 183 35 - 104 20.8 122 317 439 28 3 - 
Control 74 147 142 21 162 38.5 29 50 15.6 100 366 466 21 14 13.49 
Control 81 136 115 23 162 33.7 22.5 78 6.3 53 477 530 10 0 2.57 
Control 80 99 72 21 162 37.5 23 78 13.9 133 349 482 28 2 19.07 
Control 81 151 121 24 169 33 24.5 85 12.6 140 386 526 27 2 12.11 
Control 78 173 126 22 162 36 23.5 64 6.4 111 418 529 21 9 2.45 
Control 82 173 145 29 162 33.8 25 78 30.2 118 296 414 29 9 28.73 
Control 76 130 97 25 162 37 23 15 - - - - - - - 
Control 80 129 78 28 148 33 23 120 16 96 403 499 19 1 19.46 
Control 96 108 119 21 148 37 29 127 26.4 117 310 427 27 19 29.08 
Control 95 175 148 33 162 36.2 29 78 31.9 123 281 404 30 10 32.76 
Control 82 130 120 18 180 34.9 28 152 18.7 60 406 466 13 6 20.06 
Control 80 139 111 21 169 37 22 141 59.7 71 308 379 19 11 48.34 
Control 82 118 127 21 176 36 28 141 16.5 55 421 476 12 9 18.51 
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Control 76 142 124 18 148 34.5 20 120 10.1 27 561 588 5 2 0.01 
Control 82 134 131 24 162 34.5 26 134 11.7 146 326 472 31 2 5.43 
Control 81 120 110 23 148 38.5 37 8 39.4 86 333 419 21 15 11.13 
Control 86 152 124 27 218 33.6 22 134 16.6 90 290 380 24 5 0.28 
Control 90 195 135 20 148 36.8 23 36 13 80 400 480 17 5 14.12 
Control 88 146 93 21 169 37.2 32 57 22.1 168 235 403 42 6 39.53 
Control 81 169 134 20 162 36.2 25 99 17.6 89 397 486 18 5 17.79 
Control 83 117 109 21 176 37.9 23 92 - 245 121 366 67 2 71.08 
Control 84 118 149 22 190 34.6 24 64 46.5 104 - - - - 41.48 
Control 89 134 113 24 190 34.3 26 106 23.8 60 329 389 15 7 24.65 
Control 86 174 117 23 268 36 23 219 52.4 174 229 403 43 4 48.9 
Control 73 161 147 23 200 36.59 22.5 102 10 239 198 437 55 2 5.72 
Control 87 107 134 21 175 35.5 23.5 98 14.9 157 248 405 39 3 7.71 
Control 81 163 141 22 214 35.5 26 95 24.8 104 284 388 27 5 13.3 
Control 77 115 114 18 176 36.1 26 99 30.9 108 307 415 26 2 29.13 
Control 86 176 116 21 195 44 29 132 33.7 50 417 467 11 2 9.46 
Control 80 176 134 25 173 40.7 27.5 71 9.7 57 511 568 10 5 3.13 
Control 83 134 122 24 182 34.4 26 143 20.9 60 349 409 15 5 24.56 
Control 81 125 119 29 155 35.5 25 80 40.3 166 273 439 38 2 46.6 
Control 79 138 103 26 182 36.5 23 100 45.4 98 369 467 21 8 8.1 
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Control 79 120 99 21 182 45.1 26.5 98 43.2 86 284 370 23 6 3.66 
Control 82 113 118 22 183 36 24 134 27 61 369 430 14 5 3.11 
Control 86 165 114 24 192 37.9 23.5 126 6.5 47 474 521 9 5 40.73 
Control 88 126 141 18 179 35.2 25.5 83 48.4 105 212 317 33 6 98.04 
Control 88 145 135 24 171 36.4 27.5 117 32 61 441 502 12 27 60.34 
Control 85 167 134 25 192 35 26 83 18.7 120 402 522 23 7 42.14 
Control 83 126 114 28 205 34.8 29.5 46 19.9 165 243 408 40 4 30.29 
Control 88 128 121 19 190 36.5 25 113 6.2 20 425 445 4 6 6.92 
Control 86 149 111 32 169 34.2 34.2 49 25.2 105 285 390 27 8 21.3 
Control 80 125 123 21 166 33.7 20 107 19.4 99 358 457 22 6 4.55 
Control 80 124 117 20 187 34.2 25.5 83 48.3 85 347 432 20 3 11.28 
Control 74 108 79 22 196 38.4 22.5 72 27.3 129 290 419 31 4 17.24 
Control 78 104 108 23 194 35.5 26.5 118 27.9 98 282 380 26 16 25.8 
Control 80 151 102 23 - 36 24 - 92 83 197 280 30 7 29.73 
Control 82 101 97 22 229 34.3 23 135 31.4 163 323 486 34 2 54.51 
Control 78 82 72 25 227 34 26.5 172 15.5 173 279 452 38 4 68.99 
Control 83 104 77 18 185 35.3 21.5 39 27 41 288 329 12 27 11.8 
Control 76 127 122 21 148 37.1 28 29 19.5 127 277 404 31 4 22.21 
Control 80 137 107 22 142 39.2 27.5 98 21.9 191 283 474 40 2 23.31 
Control 82 158 121 20 185 37.9 23.5 118 14 80 375 455 18 9 11.67 
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Control 90 161 128 24 199 36.6 22 120 17.4 240 233 473 51 7 12.08 
Control 78 81 127 21 162 35.4 23 78 9.9 42 423 465 9 4 6.28 
Control 77 114 105 23 162 33.2 31 78 31.7 48 342 390 12 11 30.39 
GDM 71 215 166 21 184 34.9 22.5 100 58.9 156 261 417 37 0 21.95 
GDM 78 200 167 19 183 35.7 - 43 9.6 51 515 566 9 19 3.79 
GDM 93 82 101 20 165 33.3 26 109 9.4 29 452 481 6 2 4.91 
GDM 93 217 193 20 173 38.5 24 145 39.8 31 453 484 6 15 38.18 
GDM 92 163 127 30 190 35.9 26 162 18.1 90 348 438 21 8 38.41 
GDM 100 165 117 22 114 35.3 26 86 4.6 22 408 430 5 4 3.5 
GDM 92 140 124 24 168 37.6 28 28 9.2 98 356 454 22 20 2.15 
GDM 93 126 132 23 198 33.1 28 114 4.8 23 497 520 4 9 8.57 
GDM 106 178 156 29 170 36 27 16 17.2 218 323 541 40 15 23.1 
GDM 98 128 129 19 173 38.2 29 75 36.2 144 224 368 39 6 38.73 
GDM 97 170 108 18 196 36.7 25 84 25.3 308 13.5 321.5 96 13 34.96 
GDM 92 143 127 19 193 35.9 31 88 19.1 38 475 513 7 10 12.1 
GDM 96 176 144 25 210 38.2 28 70 5 213 326 539 40 9 1.78 
GDM 95 171 169 20 185 35.9 28.5 104 15.9 218 256 474 46 6 28.31 
GDM 96 149 131 30 176 36.7 24 71 30.3 139 337 476 29 1 45.18 
GDM 102 236 182 22 165 38 31 66 32.8 79 409 488 16 18 121.75 
GDM 80 260 234 21 118 36.5 26 57 30.8 160 315 475 34 3 39.49 
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Hct - Haematocrit 
MAC - Mid-arm circumference 
 
GDM 93 137 112 24 239 35.3 21.5 171 47.1 113 532 645 18 2 31.75 
GDM 83 178 169 23 144 42 23 55 32.3 109 217 326 33 2 21.11 
GDM 102 210 184 24 174 33.8 26.5 90 16.7 246 224 470 52 7 9.09 
GDM 95 140 173 29 162 36.7 24 27 44.9 84 321 405 21 8 11.91 
GDM 90 186 153 24 164 36 25 66 22.6 59 369 428 14 8 10.92 
GDM 81 185 134 28 215 35.7 24.5 110 18.2 58 - - - 19 8.46 
